BeiGene, Ltd. (NASDAQ:BGNE – Get Free Report) insider Xiaodong Wang sold 40,468 shares of BeiGene stock in a transaction on Tuesday, November 26th. The shares were sold at an average price of $190.10, for a total transaction of $7,692,966.80. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.
BeiGene Stock Performance
NASDAQ BGNE opened at $215.00 on Friday. The stock has a market capitalization of $20.94 billion, a price-to-earnings ratio of -26.09 and a beta of 0.63. The business’s 50 day moving average is $212.42 and its two-hundred day moving average is $184.46. BeiGene, Ltd. has a 12-month low of $126.97 and a 12-month high of $248.16. The company has a current ratio of 1.93, a quick ratio of 1.72 and a debt-to-equity ratio of 0.05.
BeiGene (NASDAQ:BGNE – Get Free Report) last released its quarterly earnings data on Tuesday, November 12th. The company reported ($1.15) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.11) by ($0.04). BeiGene had a negative return on equity of 25.12% and a negative net margin of 25.94%. The business had revenue of $1 billion during the quarter, compared to analysts’ expectations of $983.26 million. During the same quarter in the previous year, the company posted $2.01 EPS. The company’s revenue was up 28.2% compared to the same quarter last year. Research analysts expect that BeiGene, Ltd. will post -5.38 EPS for the current year.
Institutional Trading of BeiGene
Wall Street Analyst Weigh In
Several brokerages have issued reports on BGNE. StockNews.com downgraded shares of BeiGene from a “buy” rating to a “hold” rating in a research report on Thursday, November 21st. JMP Securities began coverage on BeiGene in a report on Wednesday, September 18th. They set a “market outperform” rating and a $288.00 price target on the stock. Citigroup upped their price objective on BeiGene from $269.00 to $288.00 and gave the company a “buy” rating in a research note on Thursday, August 8th. TD Cowen lifted their target price on BeiGene from $254.00 to $260.00 and gave the company a “buy” rating in a research note on Wednesday, November 13th. Finally, JPMorgan Chase & Co. upped their price target on BeiGene from $200.00 to $235.00 and gave the stock an “overweight” rating in a research note on Tuesday, October 22nd. Three investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $247.07.
Check Out Our Latest Report on BeiGene
BeiGene Company Profile
BeiGene, Ltd., through its subsidiaries, engages in the development and commercialization of oncology medicines worldwide. Its products include BRUKINSA to treat various blood cancers; TEVIMBRA to treat various solid tumor and blood cancers; PARTRUVIX for the treatment of various solid tumor malignancies; XGEVA to treat bone metastases from solid tumors and multiple myeloma, as well as giant cell tumor of bone; BLINCYTO to treat acute lymphoblastic leukemia; KYPROLIS to treat R/R multiple myeloma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia; SYLVANT to treat idiopathic multicentric castleman disease; QARZIBA to treat neuroblastoma; POBEVCY to treat metastatic colorectal cancer, liver cancer, and non-small cell lung cancer (NSCLC); BAITUOWEI, to treat breast and prostate cancers; TAFINLAR and MEKINIST to treat NSCLC and melanoma; VOTRIENT for advance renal cell carcinoma; AFINITOR for advance renal cell carcinoma, NET, SEGA, & breast cancers; and ZYKADIA to treat ALK + NSCLC.
Featured Stories
- Five stocks we like better than BeiGene
- Manufacturing Stocks Investing
- ServiceNow: Will the High-Flyer Finally Split in 2024?
- What is the FTSE 100 index?
- MarketBeat Week in Review – 11/25 – 11/29
- Biggest Stock Losers – Today’s Biggest Percentage Decliners
- These 3 Stocks Are Heavy Hitters in Alternative Asset Management
Receive News & Ratings for BeiGene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BeiGene and related companies with MarketBeat.com's FREE daily email newsletter.